334 related articles for article (PubMed ID: 24829072)
1. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
[TBL] [Abstract][Full Text] [Related]
2. Production of a novel N-terminal PEGylated crisantaspase.
Torres-Obreque K; Meneguetti GP; Custódio D; Monteiro G; Pessoa-Junior A; de Oliveira Rangel-Yagui C
Biotechnol Appl Biochem; 2019 May; 66(3):281-289. PubMed ID: 30597637
[TBL] [Abstract][Full Text] [Related]
3. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
4. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.
Modi T; Gervais D
Invest New Drugs; 2022 Feb; 40(1):21-29. PubMed ID: 34468906
[TBL] [Abstract][Full Text] [Related]
5. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
6. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
7. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
8. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.
Armstrong JK; Hempel G; Koling S; Chan LS; Fisher T; Meiselman HJ; Garratty G
Cancer; 2007 Jul; 110(1):103-11. PubMed ID: 17516438
[TBL] [Abstract][Full Text] [Related]
9. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product.
Schnuchel A; Radcke C; Theobald L; Doeding S
PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282
[TBL] [Abstract][Full Text] [Related]
10. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Willer A; Gerss J; König T; Franke D; Kühnel HJ; Henze G; von Stackelberg A; Möricke A; Schrappe M; Boos J; Lanvers-Kaminsky C
Blood; 2011 Nov; 118(22):5774-82. PubMed ID: 21940824
[TBL] [Abstract][Full Text] [Related]
11. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
12. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Avramis VI; Tiwari PN
Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
[TBL] [Abstract][Full Text] [Related]
13. Asparaginase activities during intensified treatment with pegylated
Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N
Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965
[TBL] [Abstract][Full Text] [Related]
14. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
15. PEG-asparaginase.
Fu CH; Sakamoto KM
Expert Opin Pharmacother; 2007 Aug; 8(12):1977-84. PubMed ID: 17696798
[TBL] [Abstract][Full Text] [Related]
16. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
17. Novel site-specific PEGylated L-asparaginase.
Meneguetti GP; Santos JHPM; Obreque KMT; Barbosa CMV; Monteiro G; Farsky SHP; Marim de Oliveira A; Angeli CB; Palmisano G; Ventura SPM; Pessoa-Junior A; de Oliveira Rangel-Yagui C
PLoS One; 2019; 14(2):e0211951. PubMed ID: 30753228
[TBL] [Abstract][Full Text] [Related]
18. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
[TBL] [Abstract][Full Text] [Related]
20. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
